Arkansas Blue Cross Blue ShieldCommercial · Coverage · Medical Policy · AR · Oncology, Hematology, Pulmonology +1 moreMedium impact
Policy Criteria Change
Act
by Apr 15, 2026
Effective date
Apr 15, 2026
Identified
Jun 19, 2026
Summary
Arkansas Blue Cross updated coverage criteria for multiple specialty medications including oncology drugs, asthma treatments, and CAR-T cell therapy. Key changes include new continuation criteria for several cancer drugs, updated preferred/non-preferred product lists for bevacizumab biosimilars, and one policy (Moxetumomab) being archived.
Get alerts when payers change rules like this one
We check Arkansas Blue Cross Blue Shield and other payers every day and email you when a change matches your specialty and state.
01Billing team must update prior authorization requests to reflect new continuation criteria for Enfortumab Vedotin, Romidepsin, Naxitamab, and Reslizumab.
02Update billing system to prioritize preferred bevacizumab biosimilars (Mvasi Q5107, Zirabev Q5118) over non-preferred products.
03Stop billing for Moxetumomab (Lumoxiti) as policy will be archived.
04Ensure documentation requirements for tumor response and clinical improvement are met for continuation approvals.
Codes mentioned
Q5107Q5118J9035Q5126Q5129J9999
Original notice
Policy Criteria Change
assets.contentstack.io no longer serves this document. We saved a copy on Nov 7, 2026.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.